Mechanism of Action: Fluorescence Contrast Activity
✉ Email this page to a colleague
Drugs with Mechanism of Action: Fluorescence Contrast Activity
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nxdc | GLEOLAN | aminolevulinic acid hydrochloride | FOR SOLUTION;ORAL | 208630-001 | Jun 6, 2017 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
| On Target Labs | CYTALUX | pafolacianine sodium | SOLUTION;INTRAVENOUS | 214907-001 | Nov 29, 2021 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | Y | Y | ⤷ Subscribe | ||
| On Target Labs | CYTALUX | pafolacianine sodium | SOLUTION;INTRAVENOUS | 214907-001 | Nov 29, 2021 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | Y | Y | ⤷ Subscribe | ||
| On Target Labs | CYTALUX | pafolacianine sodium | SOLUTION;INTRAVENOUS | 214907-001 | Nov 29, 2021 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | Y | Y | ⤷ Subscribe | ||
| On Target Labs | CYTALUX | pafolacianine sodium | SOLUTION;INTRAVENOUS | 214907-001 | Nov 29, 2021 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | Y | Y | ⤷ Subscribe | ||
| On Target Labs | CYTALUX | pafolacianine sodium | SOLUTION;INTRAVENOUS | 214907-001 | Nov 29, 2021 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
